

**パキシルへの転向
日本を、そして女性を**

**CONVERTING JAPAN &
CONVERTING WOMEN
TO PAXIL**

June 2010

**デービッド・ヒーリー
DAVID HEALY MD
CARDIFF UNIVERSITY**

ORGANIZATION OF TERATOLOGY INFORMATION SERVICES
奇形情報サービス機構

Home About Us Research Resources Meetings Members

Research
妊娠中の抗うつ剤
使用に関する研究

Antidepressant Use During Pregnancy Study

Antidepressants

Antidepressants are among the most commonly used medications during pregnancy. Little is known about the possible effects of continuing or discontinuing antidepressant use during pregnancy on the overall health of the mother and baby. This study is investigating the effect of discontinuing use of antidepressants during pregnancy on maternal behavior as well as on the cognitive and behavioral development of infants.

You can help!
Call: 1-877-875-7333
toll free in Canada and the US
or contact us via email:
medications.pregnancy@otiss.com
<http://pubert.ca/>

(Please include your phone number and the best time to contact you.)

抗うつ剤は妊娠中に
最も一般的に使用され
ている薬剤である





ニューヨークタイムズ

The New York Times Health

Depression Is a Dilemma for Women in Pregnancy

When Sharon Minkovitch Allen of Marietta, Ga., learned she was pregnant, she was 23, had been married for two years, had gone through two marriages and had all but given up hope of having a baby.

But instead of being overjoyed, Ms. Allen was terrified. She had been diagnosed with major depression, and she was worried that she would not have the strength to go to work in the marketing business she founded and ran, or even get through the pregnancy.

And she lived the pregnant woman's agonizing dilemma: whether to continue with the pregnancy or abort.

うつ病は妊娠中の女性にとってジレンマとなる

大うつ病と抗うつ剤治療: 妊娠及び新生児への影響

Article

**Major Depression and Antidepressant Treatment:
Impact on Pregnancy and Neonatal Outcomes**

Katherine L. Wisner, M.D.
Dorothy K.Y. Sit, M.D.
Barbara H. Hanusa, Ph.D.
Eydie L. Moses-Kolko, M.D.
Debra L. Bogen, M.D.
Diane F. Hunker, R.N.
James M. Perel, Ph.D.
Sonya Jones-Ivy, M.D.
Lisa M. Bodnar, Ph.D.
Lynn T. Singer, Ph.D.

Objective: Selective serotonin reuptake inhibitor (SSRI) use during pregnancy incurs a low absolute risk for major malformations; however, other adverse outcomes have been reported. Major depression also affects reproductive outcomes. This study examined whether 1) minor physical anomalies, 2) maternal weight gain and infant birth weight, 3) preterm birth, and 4) neonatal adaptation are affected by SSRI or depression exposure.

Method: This prospective observational investigation included maternal assessments at 20, 30, and 36 weeks of gestation. Neonatal outcomes were obtained by blinded review of delivery records and infant examinations. Pregnant women (N=286) were categorized into three mutually exclusive exposure groups: 1) no SSRI, no depression (N=131); 2) SSRI exposure (N=71), either continuous (N=48) or partial (N=23); and 3) major depressive disorder (N=36), either continuous (N=14) or partial (N=22). The mean depressive symptom level of the group with continuous depression and no SSRI exposure was significantly greater than for all other groups, demonstrating the expected treatment effect of SSRI. Main outcomes were minor physical anomalies, maternal weight gain, infant birth weight, pregnancy duration, and neonatal characteristics.

Results: Infants exposed to either SSRI or depression continuously across gestation were more likely to be born preterm than infants with partial or no exposure. Neither SSRI nor depression exposure increased risk for minor physical anomalies or reduced maternal weight gain. Mean infant birth weights were equivalent. Other neonatal outcomes were similar, except 5-minute Apgar scores.

Conclusions: For depressed pregnant women, both continuous SSRI exposure and continuous untreated depression were associated with preterm birth rates exceeding 20%.

Am J Psychiatry (学術誌)
Am J Psychiatry 2009; 166:557-566

ヘイスティングス
センターレポート
Hastings
Center
Reports

R · I · S · K
and the
Pregnant Body
妊婦の体とリスク

by ANNE DRAPKIN LYERLY, LISA M. MITCHELL,
ELIZABETH MITCHELL ARMSTRONG, LISA H. HARRIS, REBECCA
KUKLA, MIRIAM KUPPERMANN, AND MARGARET OLIVIA LITTLE

Reasoning well about risk is most challenging when a woman is pregnant, for patient and doctor alike. During pregnancy, we tend to note the risks of medical interventions without adequately noting those of failing to intervene, yet when it's time to give birth, interventions are seldom questioned, even when they don't work. Meanwhile, outside the clinic, advice given to pregnant women on how to stay healthy in everyday life can seem capricious and overly cautious. This kind of reasoning reflects fear, not evidence.

2009年12月
Dec
2009

G Koren 2007
女性の催奇形性リスクに対する感じ方
The Way Women Perceive Teratogenic Risk
The Canadian Journal of clinical pharmacology
(カナダ臨床薬理学雑誌)
Can J Clin Pharmacology 14, e10-e16



妊婦が中止
最近報告された抗うつ剤の胎児に
対する安全性に報道を心配して



pregnant pause
 With a flurry of recent reports challenging the safety of antidepressants for unborn babies, doctors and concerned mothers-to-be are rethinking the guidelines. Alexis Jetter reports.

including a small study of Paxil, the antidepressant that first made its name in 1997. The study found that Paxil was safe for use during pregnancy. But Paxil's doctors said the study was too small to be conclusive. The study's results were published in the journal *Pharmacotherapy* in the spring of 2001. "The study is inconclusive," says Dr. Robert M. Paul, a professor of obstetrics at the University of Minnesota. "But more other people have done the study, too. And I've heard some contradictory things that Paxil is a bad thing to take during pregnancy."



1962
サリドマイド
Thalidomide
ディスタヴァル
Distaval
コンテルガン
Contergan



エステス・キーフォーヴァー
Senator
Estes
Kefauver
民主党大統領選候補者
Democratic
Candidate
For Presidency
1952/1956
反トラスト委員会委員長
Chairman of
Anti-Trust
Committee

1959年キーフォーヴァーハリス公聴会
1959 Kefauver Harris Hearings

価格は固定されており高い
40億頁の広告
詐欺的広告
安全性データの差し控え
Prices Fixed and High
4 Billion pages of Adverts
Adverts Fraudulent
Withholding Safety Data

調査した77か国中、28か国が特許を認めており、
医薬品の価格は18ないし255倍高い
77 countries surveyed,
28 allowed product patents
Drug prices 18 to 255 times higher

「これらの製薬会社がロビー活動に支払う金で、
豪腕政治家もポップコーン売りのように従順になる...。あえて真実を追求する者は迫害者と非難されるだろう。」
エステス・キーフォーヴァー

“These drug fellows pay for a lobby that makes the steel boys look like popcorn vendors. ... anyone who dares seek the truth will be accused of being a persecutor”
Estes Kefauver



GATT and Patent Reform
The Global Strengthening of Patent Protection and its Implications for the Pharmaceutical Industry
TOM RAGGETT

ジェネリックの競争
特許保護

THE PATENT CLOCK 1970
GENERIC COMPETITION
PATENT PROTECTION

ガットと特許に関する改革

特許保護の世界的強化と、それが及ぼす製薬産業における意義

12

1962年の修正法
1962 Amendments

1. 処方薬剤中心政策
1 Prescription only Status
2. 比較対照試験
2 Controlled Trials
3. 病気のための薬剤
3 Drugs for Diseases

製品特許 – 知的所有権の貿易関連の側面に関する協定
Product Patents - TRIPS

13

ザンタック
Zantac
1985-1991

プロザック
Prozac
1991

リビートル
Lipitor
1997

値千金
WEIGHT
In
GOLD

14

2007

Worldwide	世界	\$663.5	100%	6.1
Oncologics	抗腫瘍剤	41.4	6.2	16.2
Lipid regulators	脂質調節剤	33.7	5.1	-6.7
Respiratory agents	呼吸器用剤	28.6	4.3	12.3
Acid pump inhibitors	プロトンポンプ阻害剤	25.6	3.9	2.8
Antidiabetics	糖尿病用剤	24.1	3.6	10.7
Antipsychotics	抗精神病剤	20.7	3.1	10.7
Antidepressants	抗うつ剤	19.7	3.0	-6.8
Angiotensin II antagonists		19.4	2.9	13.6
Anti-epileptics	抗てんかん剤	15.2	2.3	13.5
Autoimmune agents	自己免疫疾患用剤	13.3	2.0	20.3

アンジオテンシンII(受容体)拮抗剤

15

Glaxo
The **FOOD** that
BUILDS BONNIE BABIES

グラクソによる粉ミルクの広告
「健康な赤ちゃんを育てる食品」

16

これができるか？

Can **YOU** do this?

BEECHAM'S PILLS LTD
ST HELENS, LANC'S

ISSUED BY

17

**ビーチャムズ・ピル
BEECHAM'S PILLS**

これらの名高い薬はもっぱら薬草「アロエ、甘草など」から成る
These renowned pills are composed entirely of Medicinal Herbs [aloes, ginger and soap]

以下の病気を治す:便秘、頭痛、めまい、腸内ガス、疼痛、胃けいれん、背部痛、情緒不安定、不眠症、消化不良、食後膨満感、嘔吐、胃の病気、胆汁症または肝臓病、悪寒、顔面紅潮、閉塞感、全ての神経性疾患...皮膚の吹き出物...**無分別病**、腎臓ないし泌尿器疾患、月経異常

.. Cure constipation, Headache, Dizziness, Wind, Pain, and Spasms at the Stomach, Pains in the Back, Restlessness, Insomnia, Indigestion, Want of Appetite, Fullness after Meals, Vomitings, Sickness of the Stomach, Bilious or Liver Complaints, Cold Chills, Flushings of Heat, Lowness of Spirits, and all Nervous Affections.. Pimples and Blotches on the Skin...
Maladies of Indiscretion, Kidney and Urinary Disorders, and Menstrual Derangements

18

1900年2月7日 リー・トンプソン(米国リリー社重役)のメモ

「私はプロザックの安全性に対する英国の態度について得た報告を危惧している。リーバー(FDA)は、プロザックの攻撃性及び自殺念慮と英国内の他の抗うつ剤とを比較するためCSMデータベースを使うよう提案した。彼はプロザックのファンでこれらは不要なデータであると信じているが、彼は明らかに政治的な人間で圧力に対応しなければならぬだろう。」

英国で、さらに1人でも自殺の報告を受けることになれば、私どもは相応の負担を強いられることになる(商売が成り立たなくなる)ということに、パトリックが気付いて欲しいと、私は思っている。」

注: パトリック: 英国リリー社の重役

February 7, 1990 Leigh Thompson (*a) Memo

"I am concerned about reports I get re UK attitude toward Prozac safety. Leiber (FDA) suggested a few minutes ago we use CSM database to compare Prozac aggression and suicidal ideation with other antidepressants in UK. Although he is a fan of Prozac and believes a lot of this is garbage, he is clearly a political creature and will have to respond to pressures. I hope Patrick (*b) realizes that Lilly can go down the tubes if we lose Prozac and just one event (*c) in the UK can cost us that."

*a: I = Leigh Thompson - a senior manager in Lilly USA

*b: Patrick - the senior manager in Lilly UK

*c: one more suicidal event (in the UK)

19

Her body her choice...
...Your decision

1914
1951
1962
Because..

20

THE GLOBALIZATION OF THE AMERICAN PSYCHE
Crazy Like Us
ETHAN WATTERS

日本をパキシルに
転向
Converting
Japan to Paxil

2000

No SSRIs
SSRIがなければ

Taijin Kyofu
対人恐怖

21

What it is
What it feels like

このように感じたら、それは社会不安障害に違いない

パキシルは社会不安障害に効果のある唯一の処方箋薬

22

Has social anxiety put your life on hold? You are not alone.

You are not alone. 100 million Americans are suffering from social anxiety disorder. Paxil is the only medication proven effective and approved by the FDA for the treatment of social anxiety disorder.

あなた一人ではありません。1000万人を超えるアメリカ人が社会不安障害に悩んでいます。

パキシルは社会不安障害の治療のために有効性が証明されている唯一の医薬品でFDAで承認されています。

23

あなたは社会不安障害に苦しんでいますか？
詳しくは医師にお聞きたい。

Do you suffer from social anxiety disorder?
For more information, talk to your doctor.

1. Does an unreasonable fear of embarrassment cause you to avoid most social interaction? Yes No

2. Is the anxiety you feel around people so intense it sometimes feels like a panic attack? Yes No

3. Has this overwhelming anxiety significantly impaired your work or social life? Yes No

Answering these questions and discussing them with your doctor can help determine if you suffer from social anxiety disorder. Lesser degrees of social anxiety usually do not require medication.

PAXIL
PAROXETINE HCl

YOU MAY WANT TO CUT THIS OUT AND SHOW IT TO YOUR DOCTOR.

この部分を切り取って医師に見せましょう。

FDAが
全般性不安
障害に対し
承認した
初めての
そして
唯一の
SSRI

Overpowered by
ANXIETY

Empowered
by Paxil

不安で
押しつぶ
されそう

パキシル
で
力がつく

25

Still fighting
monsters

Paxil
The courage to dream

PTSD
心的外傷後ストレス障害
に対しFDAが承認

今も、モンスターと
の闘いが……

パキシル
勇気・夢へ

26

A Lunch Symposium to be held at
the American Psychiatric Association
155th Annual Meeting

ランチ・シンポジウム
米国精神医学会
第155回学術総会


Recent Developments in the
Science and Treatment of
PTSD





PTSD:
心的外傷後
ストレス障害
最近の進歩
その
科学的側面と治療

SUNDAY, MAY 16, 2002
4:30 PM - 4:30 PM

Loews Hotel
Millmonte Hall
Second Floor

27







結果判定法

MEASURING OUTCOMES


1. 疾患別の観察者による評価法
 - 1. Disease Specific Observer Ratings
 - Hamilton Depression Scale
2. 疾患別の自覚症状による評価法
 - 2. Disease Specific Subjective Ratings
 - Beck Depression Scale
3. 疾患を特定しない観察者評価法
 - 3. Disease Non-specific Observer Rating
 - Clinical Global Impression Scale
4. 疾患を特定しない自覚的評価法
 - 4. Disease Non-specific Subject Rating
 - Quality of Life Scales

降圧剤とQOL(生活の質)

Antihypertensives & Quality of Life

	改善 Improved			悪化 Worse		
	医師評価 Physician's Assessment	患者評価 Patient's Assessment	親族評価 Relative's Assessment	医師評価 Physician's Assessment	患者評価 Patient's Assessment	親族評価 Relative's Assessment
Female 女性	34	10	1	0	4	33
Male 男性	41	26	0	0	3	41
TOTAL 合計	75	36	1	0	7	74

Jachuck et al 1982



帽子から兎を取り出すための説明
INSTRUCTIONS FOR
PULLING RABBIT OUT OF HAT

- 帽子に兎を入れる
1/ PUT RABBIT IN HAT
2/

42



ぜんそく - 最大流量
Asthma – Peak Flow
脂質レベル
Lipid Levels
血糖
Blood Glucose
摂食障害
Eating Disorders
骨粗鬆症
Osteoporosis
測定結果が病気となる
The Measurement
is the Illness

43

招待状: 臨床スケールへの臨床技術:
統合失調症患者の治療のための実用的技術

YOU ARE INVITED to Attend a Symposium at the
APA 2007 Annual Meeting

CLINICAL SKILLS
to
CLINICAL SCALES:
Practical Tools in the Management of
Patients with Schizophrenia

Earn Up to 3 AMA PRA Category 1 Credits™

Saturday, May 19 - 5:30 PM
Manchester Grand Hyatt, Douglas Pavilion C/D, San Diego, CA
A complimentary dinner will be served as a part of this program.

GAIN INSIGHTS ON Effective Use of Clinical Assessments, Scales and Scales
Selection of Tailored Treatment Plans
Guidance for Incorporating Routine Assessments of Medication to Improve Patient Outcomes
And More...

Presented by the American Psychiatric Association

痛みは娘が家を出た日から始まりました。



今までに血尿が出た
ことはありますか？

45

「私たちは、標準化の手法の導入が、製造における大量生産がもたらしたと同様の情況変化をみることになるだろう。どちらも、肯定的側面と否定的側面も有するのである。」

“It may be that we are witnessing a change as revolutionary as was the introduction of standardization and mass production in manufacture. Both have their positive & negative sides”.




ハミルトン 1972
Hamilton M (1972).

46

評価尺度
Rating Scales

1. 情報の乏しいチェックリスト
1 Information poor checklists
2. 臨床的な注視を捉えること
2 Capture of Clinical Gaze
3. 偽りの学問: 計測
3 Measurement pseudo-science
4. 患者情報の軽視
4 Informational Reductionism

47



臨床試験請負会社 Clinical Research Organizations

Quintiles クインタイルズ	1982
Parexel パレクセル	1983
Covance コーヴァンス	1987

300億ドル
\$30 Billion

52

Did you know...that of the world's top 30 best-selling drugs, Quintiles helped develop or commercialise every one?

世界販売ベスト30の薬の開発/宣伝にクインタイルズが貢献してきたことをご存知ですか？

発展途上国における試験
Trials in Undeveloped Countries

私的倫理委員会
Private Ethics

マーケティング目的の試験
Marketing Trials

データアクセス
Data Access

53



科学治療薬情報社: STI

STI SCIENTIFIC THERAPEUTICS Information, Inc.

EXPERIENCE. COMMITMENT. SERVICE. RESULTS.

STIは臨床治療薬に関係した科学論文や、その他関連情報に特化し、その開発を担当する総合出版サービスグループです。

WELCOME TO STI.

STI is a full-service medical publishing group specializing in the development of scientific literature and other resource media with direct application to clinical therapeutics.

STI has been serving members of the pharmaceutical industry and medical associations since 1985.

STIは1985年から、製薬企業や医学関係学会のメンバーに対して、サービスを提供させていただいております。

We'll work with you to formulate your objectives and focus on your key data. We'll recommend ways to expand awareness and target the audience, media or journals that will best fit your goals.

聴衆、メディア、ジャーナルに注目されるよう、重要なデータに焦点を当て、貴方の目的に沿うように仕事をさせていただきます。

PIVOTAL STUDY REPORTS 重要研究論文

SCIENTIFIC MEETING ABSTRACTS AND POSTERS 学会発表の要約・ポスター作成

CLINICAL STUDY REVIEWS 臨床研究総説

PROMOTIONAL FORMULARY KITS 販促処方薬集キット

PRODUCT-SPECIFIC MONOGRAPHS 製品毎の情報集

JOURNAL PROCEEDINGS/SUPPLEMENTS 定期刊行物への会議記録 / サプリメント記事作成

ROUNDTABLE MEETINGS 円卓会議

CONSENSUS CONFERENCES コンセンサス会議

MEETINGS | PUBLICATION PLANNING | ADVOCACY DEVELOPMENT

WE CAN MEET YOUR NEEDS WHILE CONSISTENTLY EXCEEDING YOUR EXPECTATIONS.

貴方様のご期待以上の成果をお約束します。

Need to know who are the respected experts in the field served by your new product? If we don't already know them, we'll find them; and we'll help you build a relationship that serves everyone's needs.

貴方が新たに開発した製品の分野では、どなたが最も信頼され尊敬されている専門家なのか知る必要があります。もし私どもがまだ存じ上げない場合には、そのような方を探し出し、その方と接触が持てるよう、どなたのニーズにも沿う所存です。



2000年から2006年にかけて、ネメロフ医師は、グラクソスミスラインから96万ドルを超える収入を得ていたが、議会資料によれば、彼の大学の開示書式には、その間3万5000ドルに満たない収入しか記載されなかった。

From 2000 through 2006, Dr. Nemeroff earned more than \$960,000 from GlaxoSmithKline but listed earnings of less than \$35,000 for the period on his university disclosure forms, according to Congressional documents.

ニューヨークタイムズ2008年4月10日
New York Times April 10th 2008

Spring 2003 • Volume 37 • Supplement 1

Psychopharmacology BULLETIN

精神薬理学雑誌

p6 序 ……ネメロフ
p8 パロキセチンの神経薬理学…ネメロフ

6	Introduction	Charles B. Nemeroff, MD, PhD
8	Neuropharmacology of Paroxetine	Richard J. Cherm, PhD, and Charles B. Nemeroff, MD, PhD
19	In Vivo Neuroimaging Correlates of the Efficacy of Paroxetine in the Treatment of Mood and Anxiety Disorders	Christine G. Pitts
29	Pharmacokinetics, Drug Interactions, and Tolerability of Paroxetine and Paroxetine CR	C. Lenora DeBruin, PharmD
42	Paroxetine Treatment of Major Depressive Disorder and Paroxetine CR	Robert N. Golden, MD
53	Treatment of Panic Disorder: Focus on Paroxetine	Albert H. Pakiz, MD, and Steven C. Yudof, MD
64	Paroxetine Treatment of Generalized Anxiety Disorder	David F. Steiner, MD, MSc, and C. Gloria Mates, PharmD
70	Treatment of Postmenopausal Vasomotor Symptoms: The Impact of Paroxetine	Jonathan R. T. Davidson, MD
89	Obsessive-Compulsive Disorder: Implications of the Efficacy of an SSRI, Fluoxetine	Philip T. Pines, MD
97	Advances in Recognition and Treatment of Social Anxiety Disorder: A 10-Year Retrospective	Alamy A. Stone, MD, PhD, DPM
108	Paroxetine Use in Multidrug Resistant Patients	Steven Grant, MD, PhD, Wendy J. Stewart, MD, Andrew M. Miller, MD, and Douglas J. Steinhauser, MD, MS
123	Paroxetine Treatment of Depression in Late Life	Charles F. Reynolds III, MD
135	Paroxetine Treatment of Mood Disorders in Women: Perinatal Dysphoric Disorder and Hot Flashes	Christine G. Pitts, MD
148	Clinical Management of Perinatal Depression: Focus on Paroxetine	D. Jeffrey Newport, MD, MSCR, MDiv, and Zachary N. Stowe, MD
167	Paroxetine Treatment of Mood and Anxiety Disorders in Children and Adolescents	Karen Doreen Ripstein, MD, PhD
176	Efficacy and Tolerability of Controlled-Release Paroxetine	Robert N. Golden, MD

女性の気分障害のパロキセチン治療： 月経前不快気分障害と顔面紅潮

135 Paroxetine Treatment of Mood Disorders in Women: Premenstrual Dysphoric Disorder and Hot Flashes
Kimberly A. Yonkers, MD

148 Clinical Management of Perinatal Depression: Focus on Paroxetine
D. Jeffrey Newport, MD, MSCR, MDiv, and Zachary N. Stowe, MD

周産期のうつ病の臨床管理： パロキセチンを中心に

THE WALL STREET JOURNAL HEALTH

GET 2 WEEKS FREE

Emory Psychiatrist Cited in Conflicts of Interest

エモリー大学の精神科医が利益相反を指摘される

Emory University has disciplined a prominent psychiatrist who was being paid by an pharmaceutical major at the same time he was conducting federal research about the use of such drugs in pregnant women.

The university said by medical school dean issued a letter of reprimand on April 30 to psychiatrist Zachary Stowe related to his "improper relationships." Dr. Stowe was restricted to mandatory activities related to correct federal grants and was banned from having any conflicts in the future.

上院議員(グラスリー)によれば、抗うつ剤パキシルのメーカーであるグラクソスミスクラインから得た記録から、ストーリー医師は2007年には製薬会社から15万4400ドルを、2008年の最初の10ヶ月の間には9万9300ドルを支払われていたことがわかった。その総額には、会社の利益のための少なくとも95の販促講演の報酬も含まれていた。

The senator [Grassley] said records he obtained from GlaxoSmithKline PLC, the maker of the antidepressant Paxil, indicated Dr. Stowe was paid \$154,400 by the drug company in 2007 and \$99,300 during the first 10 months of 2008. The totals included payments for at least 95 promotional talks on behalf of the company.

THE GLOBALIZATION OF THE AMERICAN PSYCHE

Crazy Like Us

ETHAN WATTERS

Japan 2000

No SSRIs

妊娠 Pregnancy

女性のため第一選択抗うつ剤

THE ANTIDEPRESSANT OF CHOICE FOR WOMEN

Depression in Women: 女性のうつ病

Times for Special Consideration

特別な考慮が必要な時

- Premenstrual 月経前症
- Pregnancy 妊娠
- Postpartum 分娩後
- Perimenopause 閉経期
- Postmenopause 閉経後

Paxil パキシル
Seroxat
Paroxetine
パロキセチン

Short half life 半減期が短い
Lactation 授乳
Untreated depression 未治療のうつ病

本物のリーダーシップがなければ
True leadership has to be earned.

離脱症状のリスクを減らします

プロザックには、まれにしかない

REDUCING THE RISK OF DISCONTINUATION SYNDROME

Prozac is rarely associated with the unpleasant symptoms of antidepressant Discontinuation Syndrome. Maybe that's why Prozac has earned its status around the world.

THE JOURNAL OF CLINICAL PSYCHIATRY

SUPPLEMENT

Antidepressant Discontinuation Syndrome Update on Serotonin Reuptake Inhibitors

臨床精神医学雑誌

付録

抗うつ剤の離脱症状：セロトニン再取込阻害剤の最新情報

女性のため第一選択抗うつ剤
THE ANTIDEPRESSANT OF CHOICE FOR WOMEN

Depression in Women: 女性のうつ病

Times for Special Consideration
特別な考慮が必要な時

- Premenstrual 月経前症
- Pregnancy 妊娠
- Postpartum 分娩後
- Perimenopause 閉経期
- Postmenopause 閉経後

Short half life 半減期が短い
Lactation 授乳
Untreated depression 未治療のうつ病

Paxil パキシル
Seroxat
Paroxetine
パロキセチン

月経前症候群 & 月経前不快気分障害
PreMenstrual Syndrome & PreMenstrual Dysphoric Disorder

Primarily Physical Symptoms 主に身体症状

Primarily Mood symptoms 主に気分症状

PMDD – PreMenstrual Dysphoric Disorder

月経前不快気分障害
PreMenstrual Dysphoric Disorder

Background 背景	Symptoms 症状
<ul style="list-style-type: none"> • 75% of women report minor, isolated, occasional premenstrual changes • 75%の女性が軽い孤独感や一過性の月経前変化を時に報告 • 20 – 50% report “premenstrual syndrome” • 20-50%が「月経前症候群」を報告 • 3 – 8% of reproductive-age women have PMDD • 出産年齢女性の3-8%がPMDD 	<ul style="list-style-type: none"> • Anxiety, irritability, tension 不安、興奮性、緊張 • Affective lability 情緒不安定 • ↓ Interest 興味の低下 • ↓ Energy, fatigability 活力低下、易疲労感 • Food craving 嗜好の変化 • Bloating, breast tenderness, headaches, joint pain 腹部膨満、乳房の圧痛、頭痛、関節痛

JOURNAL OF WOMEN'S HEALTH
Volume 15, Number 2, 2006
© 2006 Ann Lippincott, Inc.


重症PMS, PMDD及び併存疾患の治療に関する専門家ガイドライン: SSRIの役割

Expert Guidelines for the Treatment of Severe PMS, PMDD, and Comorbidities: The Role of SSRIs

MEIR STEINER, M.D., Ph.D.,¹ TERI PEARLSTEIN, M.D.,² LEE S. COHEN, M.D.,³ JEAN ENDICOTT, Ph.D.,⁴ SUSAN G. KORNSTEIN, M.D.,⁵ CARLA ROBERTS, M.D., Ph.D.,⁶ DAVID L. ROBERTS, M.D.,⁷ and KIMBERLY YONKERS, M.D.⁸

ABSTRACT


The hallmark feature of premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD) is the predictable, cyclic nature of symptoms or distinct on/offness that begins in the late luteal phase of the menstrual cycle and remits shortly after the onset of menstruation. PMDD is distinguished from PMS by the severity of symptoms, predominance of mood symptoms, and role dysfunction, particularly in personal relationships and marital/family domains. Several treatment modalities are beneficial in PMDD and severe PMS, but the selective serotonin reuptake inhibitors (SSRIs) have emerged as first-line therapy. The SSRIs can be administered continuously throughout the entire month, intermittently from ovulation to the onset of menstruation, or semi-intermittently with dosage increases during the late luteal phase. These guidelines present practical treatment algorithms for the use of SSRIs in women with pure PMDD or severe PMS, PMDD and underlying subsyndromal clinical features of mood or anxiety, or premenstrual exacerbation of a mood/anxiety disorder.



乳癌患者における顔面紅潮へのパロキセチン

Paroxetine For Hot Flashes In Breast Cancer Patients

- Rationale **論拠**
 - 55% survivors have debilitating Hot Flashes
 - 55%の生存者が消耗性の顔面紅潮を有する
 - Association between Estrogen RT – breast Cancer
 - エストロゲン補充療法と乳癌との関連
 - Nonhormonal treatment disappointing
 - 下記の非ホルモン療法は期待できない
 - Bellergal, clonidine, vit. E, soy products
 - ベレルガル、クロニジン、ビタミンE、大豆製品
- Mechanism? **作用機序は？**
 - estrogen withdrawal related to ↓ serotonin
 - セロトニン低下に伴いエストロゲンが枯渇



About Us

Zach Stowe

エモリー大学
女性のための
メンタルヘルスプログラム

Emory
Women's
Mental Health Program

これらの 完全な出産経験 は
全ての妊娠の15%に満たない
These 'perfect childbirth experiences' account for less than 15% of all pregnancies





シーモア・ケティ
Seymour Kety
 アメリカ国立精神衛生
 研究所
NIMH
1968

78

「脳に生物学的手段(薬剤など)で何らかの介入する行為は、予測可能な将来開発しうるいかなるものも(電極が全く電流を通さず、薬がプラセボであったとしても、行動には何らかの影響を与えるのであるから)、プライバシーや品位、そしてかけがえのない個人の権利を強烈に侵害する。

S Kety : 第90回国会健康科学と社会に関する公聴会 : 第2セッション、p292

“The manipulation of the brain by any of the biological techniques which can be developed in the foreseeable future would involve such drastic invasions of privacy, integrity and the unalienable rights of the individual that in their application behavioral control would already have been achieved even if the electrodes carried no current and the pill were placebo”.

S Kety, Hearings of the National Commission on Health Sciences & Society, 90th Congress, Second Session. Page 292


79



医薬品と市場
Medicine & Markets

- 正しいデータの収集—患者/発見
1. Collect the Right Data – Patient/Discovery
- データへのアクセス—自由市場
2. Access to Data – Free Market
- 処方箋制度のあり方は?
3. Prescription Only?
- 製品特許に問題は?
4. Product Patents?

80



リスク及びベネフィット評価: 妊娠中の大うつ病に抗うつ剤治療をすべきか否か

Editorial

Assessing Risk and Benefit: To Treat or Not to Treat Major Depression During Pregnancy With Antidepressant Medication

バーバラ・パリー
Barbara Parry
 カリフォルニア大学
 サンディエゴ校
 UCSD
 2009

82

本物のリーダーシップがなければ
 True leadership has to be earned.




離脱症状のリスクを減らします

プロザックには、まれにしかない

REDUCING THE RISK OF DISCONTINUATION SYNDROME

Prozac is rarely associated with the unpleasant symptoms of antidepressant Discontinuation Syndrome. Maybe that's why Prozac has earned its status around the world.

83



Modern management of perinatal psychiatric disorders

Carol Henshaw, John Cox and Joanne Barton


84

周産期精神障害の最新治療

2009

未治療のうつ病のリスク
Risks of Untreated Depression

抗うつ剤のリスクはない
No Risk from Antidepressants



Wellcome

Y9C 100

THE MAGIC BULLET

85